800 tons of tires are removed and recycled from Ecatepec streetsJune 18, 2020
The 18 thousand deaths from COVID-19 in Mexico were exceededJune 18, 2020
Dexamethasone reduces death in hospitalized patients with severe respiratory complications from COVID-19
June 15th, 2020
In March 2020, the RECOVERY (Randomized Evaluation of Covid-19 Therapy) trial was established as a randomized clinical trial to evaluate a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). More than 11,500 patients from over 175 hospitals in the UK have been enrolled.
On June 8, recruitment for the dexamethasone arm was halted as, in the opinion of the Trial Steering Committee, enough patients had been recruited to determine whether or not the drug had a significant benefit.
A total of 2104 patients were randomized to receive 6 mg dexamethasone once daily (either orally or intravenously) for 10 days and compared with 4321 patients randomized to usual care alone. Among patients who received usual care alone, 28-day mortality was highest in those who required ventilation (41%), intermediate in those patients who required only oxygen (25%), and lowest among those who did not require any respiratory intervention (13%).
Translator: Martín Caballero